Disease details

臨床試験数 : 3,342 / 薬物数 : 2,355 - (DrugBank : 406) / 標的遺伝子数 : 269 - 標的パスウェイ数 : 241

2 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05000216 (ClinicalTrials.gov)	August 13, 2021	6/8/2021	COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders	Booster Effects With Autoimmune Treatments in Patients With Poor Response to Initial COVID-19 Vaccine (ACV01)	Rheumatoid Arthritis;Systemic Lupus Erythematosus (SLE);Pemphigus Vulgaris;Multiple Sclerosis;Systemic Sclerosis (SSc)	Biological: Moderna mRNA-1273;Biological: BNT162b2;Biological: Ad26.COV2.S;Drug: IS (MMF or MPA);Drug: IS (MTX);Biological: IS (B cell depletion therapy)	National Institute of Allergy and Infectious Diseases (NIAID)	Autoimmunity Centers of Excellence;Rho Federal Systems Division, Inc.	Recruiting	18 Years	N/A	All	600	Phase 2	United States
2	NCT04952766 (ClinicalTrials.gov)	March 29, 2021	16/6/2021	Study Evaluating SARS-CoV-2 (COVID-19) Humoral Response After BNT162b2 Vaccine in Immunocompromised Adults Compared to Healthy Adults	Study Evaluating SARS-CoV-2 (COVID-19) Humoral Response After BNT162b2 Vaccine in Immunocompromised Adults Compared to Healthy Adults	Kidney Transplant;Myeloma;Cancer;Hematologic Malignancy;Multiple Sclerosis;Hypergammaglobulinemia;Malignant Tumor;Hiv;Diabetes Type 2	Biological: Biological samples	Centre Hospitalier Régional d'Orléans	NULL	Recruiting	18 Years	N/A	All	240	Phase 4	France